Deferasirox
| Evidence Level: L5 | Predicted Indications: 53 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Deferasirox |
| DrugBank ID | DB01609 |
| Brand Names (EU) | Deferasirox Accord, Deferasirox Mylan |
| Evidence Level | L5 |
| Predicted Indications | 53 |
| Top Prediction Score | 99.40% |
Approved Indication (EMA)
Deferasirox Mylan is indicated for the treatment of chronic iron overload due to frequent blood transfusions (?7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (?7 ml/kg/month of
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HIV infectious disease | 99.40% | DL |
| 2 | chronic hepatitis C virus infection | 99.39% | DL |
| 3 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.23% | DL |
| 4 | obsolete familial combined hyperlipidemia | 99.20% | DL |
| 5 | dermatofibrosarcoma protuberans | 99.11% | DL |
| 6 | feline acquired immunodeficiency syndrome | 98.96% | DL |
| 7 | simian immunodeficiency virus infection | 98.96% | DL |
| 8 | beta-thalassemia with other manifestations | 98.59% | DL |
| 9 | pyropoikilocytosis, hereditary | 98.55% | DL |
| 10 | pyruvate kinase deficiency of red cells | 98.50% | DL |
| 11 | hemoglobinopathy | 98.50% | DL |
| 12 | sitosterolemia | 98.48% | DL |
| 13 | Plasmodium falciparum malaria | 98.47% | DL |
| 14 | homozygous familial hypercholesterolemia | 98.33% | DL |
| 15 | partial deletion of the short arm of chromosome 16 | 98.26% | DL |
| 16 | hemolytic anemia due to glucophosphate isomerase deficiency | 98.24% | DL |
| 17 | gout | 97.16% | DL |
| 18 | fibroblastic neoplasm | 97.10% | DL |
| 19 | hepatitis B virus infection | 97.09% | DL |
| 20 | conventional fibrosarcoma | 96.98% | DL |
Showing top 20 of 53 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.